Articles

At the 2023 ASRS annual meeting, Nancy Lurker, Executive Vice-Chair of the Board of EyePoint Pharmaceuticals, discussed the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901.

At the 2023 ASRS annual meeting, Aleksandra Rachiskaya, MD, spoke about time to fluid control with faricimab arms complete compared to aflibercept in recent studies.

Faricimab could lower treatment burden for patients compared to aflibercept

Novel concept: inner choroid/outer retina neurovascular unit

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

At the 2023 ASRS annual meeting in Seattle, Washington, Ursula Schmidt-Erfurth, MD, shared the latest information on the GALE extension study.

This year’s meeting will include boxing rings, ball gowns and a full schedule of engaging new symposia

Durga Borkar, MD, MMCi, discussed the FARETINA-DME study during the 2023 ASRS meeting in Seattle, Washington.

Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

At the 2023 ASRS annual meeting, Dante Pieramici, MD, spoke with our team to share information on OPT-302, or sozinibercept, for the treatment of neovascular AMD and other retinal vascular diseases.

Our team spoke with Shawn Kavoussi, MD, at the 2023 ASRS meeting in Seattle, Washington about his research on using infrared video for vitreous opacities and comparing postoperative reduction in vitreous opacity scores using infrared video with the Heidelberg spectralis unit.

Michael Ip, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington. He noted presentations and trends that are key at this event and why they're vital to a modern view of ophthalmology.

Diana Do, MD, spoke with our team at the 2023 ASRS meeting in Seattle, Washington, to discuss the 2-year data on the PHOTON study, which involved 8 milligrams of aflibercept for diabetic macular oedema.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

Carl Danzig, MD, shared the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy at the 2023 ASRS meeting.

At the 2023 ASRS meeting in Seattle, Washington, Aaron Lee, MD, shared how new techniques are expanding the options for deep learning in ophthalmology.

Richard B. Rosen, MD, shared insights from his presentation from ASRS 2023 on "New 'MacGyver-inspired' endolaser option for chandelier-assisted scleral buckles" with Sheryl Stevenson, our Group Editorial Director.

Cindy Cai, MD, shared insights from her presentation from ASRS 2023, "Health disparities in lapses in diabetic retinopathy care," with Sheryl Stevenson, our Group Editorial Director.

This study of patients was designed to identify unexpected adverse effects of these new pharmacologic therapies that may not have been observed or anticipated during clinical research trials. The studied drugs were biosimilars to the reference drug ranibizumab.

Jennifer I. Lim, MD, FARVO, FASRS shares insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis."

Our team caught up with Baruch Kupperman, MD, PhD to learn about his ASRS presentation, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease."

The presenter, Jeffrey S. Heier, MD, Director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston, and an investigator in ARCHER will deliver the data on July 30, 2023.

The company announced it has scheduled an End-of-Phase 2 meeting with the FDA in Q4 2023 to discuss the specifics of the APX3330 development program.

Researchers indicated OCT can be vital to a timely diagnosis and treatment for scleritic patients.

According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.

The Biocon Biologics, Ltd product moves on to review by the European Commission, with an expected decision in late September 2023.

According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on 31 July, 2023 in Seattle, Washington.